Detail akcie Vivani Medical Rg online

Business Summary: Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vivani Medical Inc revenues was not reported. Net loss increased 15% to $20M. Higher net loss reflects Research and Development, net increase of 20% to $12.9M (expense), General and administrative increase of 9% to $6.9M (expense), Other income decrease of 2% to $768K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.32 to -$0.34.